Literature DB >> 10386631

Influence of the hypoxic subvolume on the survival of patients with head and neck cancer.

P Stadler1, A Becker, H J Feldmann, G Hänsgen, J Dunst, F Würschmidt, M Molls.   

Abstract

PURPOSE: Tumor hypoxia is regarded as an important factor influencing radiation response, disease-free, and overall survival of patients with squamous cell carcinoma of the head and neck (SCCHN). This study was performed to reevaluate the prognostic significance of the "classical oxygenation parameters" hypoxic fraction (percentage of pO2 values < 5 mmHg or < 2.5 mmHg, respectively) and median pO2, and to determine the influence of a new radiobiological factor. This factor was termed the "hypoxic subvolume" (HSV) and was defined as percentage of pO2-values below 5 mmHg multiplied by the total tumor volume. The rationale of this parameter was to quantify approximately the amount of hypoxic tissue which should be correlated to the number of hypoxic cells in the tumor. It is obvious that a tumor of 100 cm3 with a hypoxic fraction of 20% (HSV = 20 cm3) contains more hypoxic cells than a tumor of 1 cm3 with a hypoxic fraction of 50% (HSV = 0.5 cm3). METHODS AND MATERIALS: Pretreatment pO2 was assessed in 59 patients with SCCHN with the Eppendorf histograph, and pretreatment volume was determined by ultrasonography (lymphnode metastases) and computer tomography (primaries). All patients were referred to our departments for radiotherapy (n = 27, median dose 70 Gy) or radiochemotherapy (n = 32; 5-FU, mitomycin C, median dose 70 Gy), respectively. All parameters were evaluated using the Kaplan-Meier analysis, and significance was assumed at a p-value of < 0.05 (log-rank test, Cox-Mantel). A multivariate analysis was performed to control for confounding factors. The median follow-up was 233 days. At the time of the evaluation, 34 of the 59 patients were dead.
RESULTS: In univariate analyses, the hypoxic fraction (pO2 < 5 mmHg, PO2 < 2.5 mmHg [p < 0.05]), the hemoglobin concentration (p < 0.05), and the hypoxic subvolume (p < 0.01) were of prognostic significance for overall survival. In multivariate analysis, the hemoglobin concentration and the hypoxic subvolume (p = 0.01) were significant prognosticators. We found no significant correlation between tumor volume or median pO2 and overall survival. No clear correlation was found between tumor volume and hypoxic fraction.
CONCLUSION: These data suggest that the total amount of hypoxic tissue, as determined by the hypoxic subvolume, influences the prognosis of patients suffering from SCCHN. In addition, our data confirm the statements of previous studies that low pretherapy pO2-values indicate a worse prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10386631     DOI: 10.1016/s0360-3016(99)00115-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  54 in total

Review 1.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

2.  The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages.

Authors:  K L Talks; H Turley; K C Gatter; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

4.  Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions.

Authors:  Qiliang Cai; Ke Lan; Subhash C Verma; Huaxin Si; Doug Lin; Erle S Robertson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.

Authors:  O Pradier; K Lederer; A Hille; E Weiss; H Christiansen; H Schmidberger; C F Hess
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-23       Impact factor: 4.553

Review 6.  Impact of anemia in patients with head and neck cancer treated with radiation therapy.

Authors:  Kenneth Hu; Louis B Harrison
Journal:  Curr Treat Options Oncol       Date:  2005-01

Review 7.  The promise of dynamic contrast-enhanced imaging in radiation therapy.

Authors:  Yue Cao
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

8.  Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.

Authors:  Wenli Wang; Nancy Y Lee; Jens-Christoph Georgi; Manoj Narayanan; Jose Guillem; Heiko Schöder; John L Humm
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 9.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

10.  A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.

Authors:  C P Lee; G S Payne; A Oregioni; R Ruddle; S Tan; F I Raynaud; D Eaton; M J Campbell; K Cross; G Halbert; M Tracy; J McNamara; B Seddon; M O Leach; P Workman; I Judson
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.